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AMP-activated protein kinase (AMPK) is a metabolic stress-
sensing kinase. We previously showed that glucose deprivation
induces autophosphorylation of AMPKβ at Thr-148, which
prevents the binding of AMPK to glycogen. Furthermore, in
MIN6 cells, AMPKβ1 binds to R6 (PPP1R3D), a glycogen-
targeting subunit of protein phosphatase type 1 (PP1), thereby
regulating the glucose-induced inactivation of AMPK. In
the present study, we further investigated the interaction of
R6 with AMPKβ and the possible dependency on Thr-148
phosphorylation status. Yeast two-hybrid (Y2H) analyses and co-
immunoprecipitation (IP) of the overexpressed proteins in human
embryonic kidney (HEK) 293T) cells revealed that both AMPKβ1
and AMPK-β2 wild-type (WT) isoforms bind to R6. The
AMPKβ–R6 interaction was stronger with the muscle-specific
AMPKβ2-WT and required association with the substrate-
binding motif of R6. When HEK293T cells or C2C12 myotubes
were cultured in high-glucose medium, AMPKβ2-WT and R6
weakly interacted. In contrast, glycogen depletion significantly
enhanced this protein interaction. Mutation of AMPKβ2 Thr-148
prevented the interaction with R6 irrespective of the intracellular
glycogen content. Treatment with the AMPK activator oligomycin
enhanced the AMPKβ2–R6 interaction in conjunction with
increased Thr-148 phosphorylation in cells grown in low-glucose
medium. These data are in accordance with R6 binding directly
to AMPKβ2 when both proteins detach from the diminishing
glycogen particle, which is simultaneous with increased
AMPKβ2 Thr-148 autophosphorylation. Such a model points to a
possible control of AMPK by PP1-R6 upon glycogen depletion in
muscle.
Key words: AMP-activated protein kinase (AMPK), glycogen
metabolism, glycogen targeting, phosphorylation, protein–protein
interaction, R6.
INTRODUCTION
Muscular tissue, in particular skeletal muscle, is an important site
for glucose storage. It has become evident that glucose disposal
into glycogen is essential for co-ordinated glucose homoeostasis,
as conditions limiting glycogen synthesis are associated with,
for instance, hyperglycaemia and insulin resistance [1]. AMP-
activated protein kinase (AMPK) is a metabolic energy sensor
that mediates insulin-independent glucose transporter 4 (GLUT4)
translocation to the plasma membrane resulting in increased
glucose uptake [2]. Therefore, AMPK activation could normalize
blood glucose levels in Type 2 diabetic patients. In response to
various cellular stresses (e.g. contraction, nutrient deprivation),
AMPK is activated and modulates downstream targets to induce
catabolic ATP-producing processes and inhibit anabolic ATP-
consuming processes, thereby restoring energy homoeostasis.
AMPK consists of three subunits: the catalytic α subunit and
two regulatory β and γ subunits; the latter are essential for
regulating AMPK activity, as well as subcellular localization.
AMPK subunits occur in different isoforms (α1 and α2; β1 and
β2; γ 1, γ 2 and γ 3) partly showing a tissue-specific expression
pattern. Namely, β2 is the predominant isoform found in heart and
skeletal muscle [3,4]. Accordingly, it has been reported that β1-
knockout mice have a minimal phenotype in skeletal muscle [5],
whereas β2-knockout mice have reduced skeletal muscle AMPK
activity, exercise capacity and glucose uptake [6,7].
AMPK is known to shuttle between the nucleus [8,9] and the
cytoplasm [10,11], suggesting that AMPK exerts compartment-
specific effects in order to monitor and co-ordinate complex cell
biological processes. The β subunit carbohydrate-binding module
(CBM) allows AMPK to associate with glycogen [12,13], where it
interacts with other glycogen-binding proteins including glycogen
synthase (GS) [13] and glycogen phosphorylase (GP) [12].
Notably, β2 shows higher affinity for glycogen compared with
β1 [14]. Acute 5-aminoimidazole-4-carboxamide ribonucleotide
(AICAR)-induced AMPK activation inactivates GS via Ser-7
phosphorylation in skeletal muscle [15], although high levels of
glucose 6 phosphate can override this inhibition [16].
The regulation of the activity status of localized AMPK is
dependent on allosteric activation/repression and the action of
upstream kinases capable of phosphorylating Thr-172 in the
catalytic α subunit (e.g. LKB1, TAK1 and CaMKK2). Several
protein phosphatases (e.g. PP1, PP2A and PP2C) dephosphorylate
Thr-172, thus leading to AMPK inactivation. PP1 is an important
Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK, AMP-activated protein kinase; CBM, carbohydrate-binding module; CIP,
calf intestine phosphatase; DMEM, Dulbecco’s modified Eagle’s medium; EV, empty vector; G147R, Gly-147 residue for arginine; GM, growth medium;
GP, glycogen phosphorylase; GS, glycogen synthase; HEK, human embryonic kidney; HRP, horseradish peroxidase; iFBS, heat-inactivated fetal bovine
serum; IP, immunoprecipitation; ORF, open reading frame; PP1, protein phosphatase type 1; PPP1R3C, PTG/R5; R6, glycogen-targeting subunit PPP1R3D;
Reg1, yeast-targeting subunit of PP1; Snf1, sucrose-non-fermenting 1; T148D, Thr-148 residue with aspartate; WT, wild-type; Y2H, yeast two-hybrid; β-CD,
β-cyclodextrin.
1 To whom correspondence should be addressed (email d.neumann@maastrichtuniversity.nl).
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protein phosphatase in mammalian cells that is involved in proper
co-ordination of glycogen metabolism by dephosphorylating
target enzymes such as GS and GP. Recruitment of PP1 to
its target substrates and to glycogen occurs by means of its
glycogen-targeting proteins, such as PTG/R5 (PPP1R3C) [17]
or R6 (PPP1R3D) [18,19]. Insight into PP1-mediated AMPK
regulation came from our previous study [20], which showed
that R6 physically interacts with the AMPKβ1 subunit, resulting
in glucose-induced AMPK dephosphorylation by the PP1-R6
complex. Furthermore, we found that the CBM domain within
the AMPKβ1 subunit is required for interaction with R6, as
substitution of arginine for Gly-147 (G147R) resulted in total
loss of AMPK–R6 interaction [20]. These results were consistent
with parallel studies in yeast showing that sucrose-non-fermenting
1 (Snf1) is regulated by glucose, and that Gal-83 via its
CBM interacts with yeast-targeting subunit of PP1 (Reg1), the
orthologues of AMPKβ and R6, respectively [21], thus pointing
to an evolutionarily conserved mechanism.
We recently reported that autophosphorylation of Thr-148 in
the AMPKβ subunit interferes with the recruitment of AMPK
to glycogen, suggesting that AMPK–glycogen localization is
tightly regulated and linked to glycogen storage [22]. Given the
direct binding of AMPKβ1 to R6 and the observed loss of this
interaction using the AMPKβ1-G147R mutant, we hypothesized
a role for AMPKβ Thr-148 phosphorylation. In the present study,
we provide insight into the binding of AMPKβ2 to R6 in relation
to glycogen content and AMPKβ2 Thr-148 phosphorylation. Our
results indicate that the AMPKβ2–R6 interaction is dynamically
controlled by glycogen content.
MATERIALS AND METHODS
Plasmids
For expression in mammalian cells, the cDNA of full-length
AMPKβ1 and AMPKβ2 was amplified by PCR and ligated
in-frame into the pmCherry expression vector (Clontech) via
EcoRI and SalI restriction sites, as previously described [22]. An
AMPKβ2–mCherry construct bearing a threonine-to-aspartate
mutation on residue 148 (T148D) was generated using the Quik
Change site-directed mutagenesis kit (Stratagene). The pcDNA3
constructs for expression of AMPKγ 1 and myc–AMPKα1 were
kindly provided by Dr D. Carling (Imperial College London,
London, U.K.). The corresponding open reading frame (ORF) of
AMPKβ2-T148D mutant was subcloned into pBTM116 to allow
for expression in yeast (LexA-AMPKβ2-T148D). The pFLAG-
R6 construct for mammalian expression of R6-wild type (WT)
and R6 mutants (R6-RARA, -RAHA, -WDNAD and -WANNA)
were generated as previously described, and pFLAG was used as
empty vector (EV) control [20,23].
Other plasmids used for yeast two-hybrid (Y2H) analyses
were pGADT7- (GAD, empty plasmid), pGADT7-R6
(GAD-R6), pBTM-R6 (LexA-R6), pBTM-R6-RARA (LexA-




(LexA-AMPKβ1), pBTM-AMPKβ2 (LexA-AMPKβ2) [20,
23–25].
For retroviral overexpression and optimal detection of
exogenous β2, full-length AMPKβ2-WT or AMPKβ2-T148D
was amplified using PCR primers containing an optimized tetra-
cysteine sequence (FlAsH-tag; FLNCCPGCCMEP). First, the
corresponding ORF (FlAsH-tag) was subcloned into the SalI
and NotI site of the mammalian β2-WT–mCherry or β2-T148D–
mCherry construct, exchanging the mCherry tag for a FlAsH tag.
Secondly, β2-WT–FlAsH or β2-T148D–FlAsH was amplified
and subcloned into the EcoRI and SalI sites of the retroviral
pBabe-puromycin backbone (kindly provided by Dr G. Nolan,
Stanford University, CA, U.S.A.).
For retroviral overexpression of R6, the corresponding ORF
(R6-WT) was amplified by PCR and subcloned into the BstXI and
SalI restriction sites of the pBabe-puromycin retroviral backbone
(kindly provided by Dr G. Nolan, Stanford University, CA,
U.S.A.). The pBabe-puromycin EV was used as control. Primer
sequences are available from D.N. upon request. All of the
constructs were verified by DNA sequencing.
Cell culture
The human embryonic kidney (HEK) 293T cell line was
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with
high glucose (25 mM) (Gibco), supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (iFBS, Bodinco) and 1%
penicillin/streptomycin (Invitrogen), unless otherwise stated. For
transient transfections, HEK293T cells were seeded to 30%
confluence in six-well plates (Greiner Bio-one) 24 h before
transfection. For determination of protein–protein interactions,
cells were co-transfected with AMPK (α1–myc, γ 1 and β1-
WT–mCherry or β2-WT/β2-T148D–mCherry), and/or FLAG–
R6 (R6-WT/R6-RARA/R6-RAHA/R6-WANNA/R6-WDNAD)
or FLAG EV plasmid DNA using Lipofectamine 2000
(Invitrogen) in antibiotic-free culture medium. At 6–8 h after
transfection, transfection medium was replaced by normal growth
medium (GM). At 48–72 h after transfection and continuous
culturing (i.e. without change of medium), cells were harvested for
glycogen or subjected to immunoprecipitation (IP) and Western
blotting.
In order to induce glycogen depletion, HEK293T cells growing
in high-glucose medium (DMEM with 25 mM glucose and 10 %
iFBS), were subjected to forskolin treatment (100 μM, Sigma),
low-glucose medium (DMEM with 3 mM glucose and 10%
iFBS) or glucose-deprived medium (DMEM and 10 % iFBS
without glucose) for 16 h. To activate AMPK, cells were serum-
starved in high- or low-glucose medium for 16 h, and subsequently
treated with oligomycin (3 μM, Sigma) for 1 h.
The mouse skeletal muscle cell line C2C12 was kindly
provided by Dr R.C. Langen (Maastricht University, Maastricht,
The Netherlands). C2C12 cells were continuously cultured
to approximately 80% confluence in DMEM with high
glucose (25 mM) (Gibco), supplemented with 10% (v/v)
iFBS and 1 % penicillin/streptomycin. For differentiation into
myotubes, myocytes (75–85% confluence) were further grown
in differentiation medium (DMEM with 25 mM glucose
(Gibco), supplemented with 2% heat-inactivated horse serum
(Invitrogen/Life Technologies) and 1% penicillin/streptomycin
(Invitrogen) for 4–5 days. Subsequently, cells were used in
the corresponding experiments. In order to induce glycogen
depletion, myotubes were maintained in low-glucose medium
(DMEM with 3 mM glucose, supplemented with 2% iFBS), for
16 h. In order to activate AMPK, myotubes were maintained in
high or low glucose for 16 h as described above, and subsequently
treated with oligomycin (5 μM) for 30 min.
Retroviral infections
In order to study protein–protein interactions in C2C12 myotubes,
growing cells were infected with FlAsH-tagged AMPKβ2-WT
or -T148D, or FLAG-tagged R6 retrovirus. Briefly, retroviral
systems and Phoenix helper-free retrovirus producer cell lines
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were used as described previously [26–28]. Amphotropic
retroviral supernatants were produced as previously described
[22]. Briefly, 24–48 h after calcium phosphate/DNA transfection
of producer cells, supernatants were harvested, filtered (0.45 μm
filters; Corning) and used for infection of C2C12 cells in the
presence of 4 μg/ml polybrene (Sigma). For infections, cells
were incubated with virus particles for 6–8 h and then allowed to
recover for 48 h on fresh medium, before selection pressure was
applied. Stably infected cells were selected 2 days post-infection
with 4 μg/ml puromycin for 36–48 h preceding experiments.
Immunoprecipitation and Western blotting
IP procedures were performed as previously described [22].
Briefly, exogenous myc–AMPKα1 was immunoprecipitated
using anti-myc-tag antibody (9B11, Cell Signaling Technology),
exogenous R6 was immunoprecipitated using anti-FLAG-
tag antibody (F3165, Sigma) and endogenous AMPK was
immunoprecipitated using a combination of anti-AMPKα1 and
anti-AMPKα2 antibodies raised in sheep (kindly provided
by Dr D.G. Hardie, University of Dundee, Dundee, UK),
followed by incubation with Protein G–Sepharose beads (GE
Healthcare). Western blot analysis was carried out using
primary antibodies against the following: myc-tag, total AMPKα,
AMPKβ1, AMPKβ2, phospho-AMPK-Thr-172 (all from Cell
Signaling Technology), FLAG-tag (F3165, Sigma), and phospho-
AMPKβ2-Thr-148 [22]. Detection was performed according to its
primary antibody using anti-rabbit (Cell Signaling Technology)
and anti-mouse (Dako) horse radish peroxidase (HRP)-conjugated
secondary antibodies, followed by chemiluminescence.
In order to investigate the role of glycogen, myc–AMPKα1
was immunoprecipitated using the anti-myc-tag antibody after
the addition of the glycogen mimic β-cyclodextrin (β-CD; 5 mM,
Sigma) for 1 h at 4 ◦C. Subsequently, immune complexes were
electrophoresed by SDS/PAGE and analysed by Western blot
analysis, as described above.
Biochemical intracellular glycogen measurement
Intracellular glycogen content was measured, as previously
described [22]. Briefly, HEK293T cells (non-transfected or
transfected) or stably infected C2C12 myotubes were lysed in
potassium hydroxide (30%) and boiled at 70 ◦C for 30 min.
Subsequently, samples were cooled to 25 ◦C before sodium sulfate
(6%, w/v) and ethanol (99.5%, v/v) were added at a 1:1:3 ratio.
After thorough mixing, samples were rotated top-over-top at 4 ◦C
for 30–60 min. The precipitate was collected by centrifugation
at 2300 g (Eppendorf Centrifuge 5415 R) for 5 min at 4 ◦C. To
hydrolyse glycogen, pellets were dissolved in 1 M HCl and boiled
at 100 ◦C for 2 h. Samples were cooled before neutralization
using 2 M sodium hydroxide. Hydrolysates were used for glucose
determination using a glucose assay kit (Sigma), according to the
manufacturer’s instructions.
Determination of glucose uptake
The glucose uptake protocol was adapted from earlier work
[29]. Briefly, stably infected C2C12 myotubes were incubated
with the uptake buffer containing deoxy-D-glucose (4 μM), with
tracer amounts of 3H-labelled 2-deoxy-D-glucose, for 10 min.
Surplus substrate was removed by washing the cells with ice-cold
uptake buffer and cells were lysed in 0.1 M sodium hydroxide.
Incorporated glucose was assessed by scintillation counting of 3H
in lysates.
Preparation of skeletal muscle tissue homogenates
Gastrocnemius muscle was taken from one female WT C57/BL6
mouse of the regular Maastricht University breeding programme,
which was approved by the Animal Ethics Committee of
Maastricht University and performed according to the Dutch
regulations. After killing, tissues were freeze clamped between
aluminium tongs pre-cooled in liquid nitrogen and stored at
− 80 ◦C until analysis. Muscle extract was prepared essentially as
previously described [30]. Briefly, the tissue sample was extracted
in SET buffer (250 mM sucrose, 2 mM EDTA and 10 mM
Tris/HCl pH 7.4) in the presence of protease and phosphatase
inhibitors (Complete and PhosStop; Roche) by homogenization
and ultrasound treatment, followed by centrifugation. Supernatant
was used for IP (see above) using the indicated antibodies.
Yeast two-hybrid analyses
Y2H analysis was performed as previously described [20,24].
Briefly, interaction analysis using yeast THY-AP4 strain
(MATa, ura3, leu2, lexA::lacZ::trp1, lexA::HIS3, lexA::ADE2)
co-transformed with the indicated combination of plasmids
(see above). Transformants were grown in selective 4 %
glucose synthetic complete medium lacking the corresponding
supplements to maintain selection for plasmids. The strength
of the interaction was determined by measuring β-galactosidase
activity in permeabilized yeast cells and expressed in Miller units.
In all Y2H analyses, similar protein levels were obtained from the
expression constructs, as verified in the crude extracts from
the different yeast transformants.
Statistical analysis
All plotted data are presented as means +− S.E.M., unless
otherwise stated. Statistical differences were evaluated using
unpaired Student’s t test and statistical analysis software Prism 4
(GraphPad Software). P values equal to or less than 0.05 were
considered statistically significant.
RESULTS
R6 preferentially interacts with AMPKβ2
We previously demonstrated that R6 (PPP1R3D), one of the
glycogen-targeting subunits of PP1, physically interacts with
AMPKβ1 in MIN6 pancreatic β cells [20]. To verify AMPKβ1–
R6 interaction in HEK293T cells, we overexpressed myc-tagged
AMPK heterotrimers (myc–α1, β1–mCherry, γ 1), together with
FLAG-tagged R6 (FLAG–R6) or EV control. Physical interaction
between AMPKβ1 and R6 was assessed by IP of AMPK from
cells that were routinely cultured under glucose-rich conditions
(25 mM glucose) (Figure 1A). Pull-down of myc–AMPKα1
resulted in co-IP of both mCherry-tagged AMPKβ1 (65 kDa)
and FLAG-tagged R6, indicating formation of the heterotrimeric
AMPK complex and the interaction with R6 (Figure 1A). As
expected, FLAG–R6 signal was absent from cells transfected
with EV. Next, we investigated the interaction between muscle-
specific AMPKβ2 heterotrimers (myc–α1, β2–mCherry, γ 1)
and R6 (FLAG–R6) using co-transfection and IP in HEK293T
cells. As both proteins co-immunoprecipitated, this data points
to the occurrence of a physical interaction between R6 and
AMPKβ2 (Figure 1B). Interestingly, co-IP appeared stronger in
the presence of AMPKβ2 compared with β1. These data were
further confirmed by Y2H analyses: in Figure 1C it is shown that
R6 binds to both AMPKβ1 and AMPKβ2, whereas the interaction
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Figure 1 R6 preferentially interacts with AMPKβ2
(A and B) HEK293T cells transiently overexpressing FLAG–R6 and heterotrimers of AMPKβ1 (myc–α1, γ 1, AMPKβ1–mCherry) (A) or AMPKβ2 (myc–α1, γ 1, AMPKβ2–mCherry) (B). FLAG EV
was used as control. Cells were continuously cultured under high-glucose (25 mM) conditions and harvested 56 h post-transfection. Interaction between AMPKβ1/AMPKβ2 and R6 was assessed by
immunoprecipitating the heterotrimeric AMPK complex from 800 μg of lysate using the anti-myc-tag antibody. Western blots were assessed using the indicated antibodies. Representative Western
blots are shown. (C) Yeast THY-AP4 strain (see the Materials and methods section) was transformed with the indicated combination of plasmids. Transformants were grown in high-glucose (4 %
glucose) medium and protein interactions were estimated by measuring the β-galactosidase activity. EV pGADT7 (GAD-) served as control. Values correspond to means from at least six different
transformants (bars indicate S.D.). *P < 0.001 compared with LexA-AMPKβ1-WT + GAD-R6.
between AMPKβ2 and R6 is significantly stronger than the
one between AMPKβ1 and R6. Combined, these findings suggest
that R6 prefers interaction with AMPKβ2 over AMPKβ1.
R6 interaction with AMPKβ2 requires its substrate-binding motif
Recently, a number of functionally distinct protein domains have
been identified in the R6 glycogen-targeting subunit of PP1 [23].
R6 is composed of domains that mediate binding to carbohydrates
(via its CBM), binding to the PP1 catalytic subunit (PP1c; RVXF
motif), and to the glycogen metabolism-related substrates of PP1
(via the highly conserved WDNND motif). To investigate whether
and which of these motifs are involved in the interaction between
the AMPKβ subunit and R6, we performed studies in HEK293T
cells co-expressing AMPKβ2 complex (myc–α1, β2–mCherry,
γ 1) with FLAG–R6, the latter carrying various mutations
corresponding to its protein motifs [23] (Figures 2A and 2B). We
again immunoprecipitated myc–AMPKα1 using a myc-directed
antibody. Of note, endogenous R6 was not detected either in
lysate or in immunoprecipitated material, thereby substantiating
the need for FLAG–R6 overexpression to study the interaction
between AMPKβ2 and R6 (Figure 2B: EV condition). R6
carried various domain-specific mutations: in both R6-RARA and
R6-RAHA mutants, the hydrophobic valine and phenylalanine
residues within putative R6-RVXF motifs were replaced by
alanine, allowing us to probe the role of the PP1-binding motif in
AMPKβ2–R6 binding (Figure 2B). R6-RARA, a mutant known
to have lost its capacity to bind to endogenous PP1c but not to
PP1 substrates [23], presented a similar AMPKβ2-binding profile
compared with WT, non-mutated R6 (R6-WT; Figure 2B, right
panel). The R6-RAHA mutant that carried mutations in a domain
close to the substrate-binding motif, however, had completely
lost its ability to interact with AMPK (Figure 2B, right panel).
These data were reproduced in a reciprocal Y2H assay using
AMPKβ2 as bait (Figure 2C). Furthermore, the substrate-binding
motif (WDNND) was mutated to study its effect on AMPKβ2–
R6 interaction. In one of the mutants, the two aspartate residues
present within the WDNND motif were replaced by alanine (R6-
WANNA mutant), whereas in the R6-WDNAD mutant the second
asparagine residue was replaced by alanine. Whereas the R6-
WDNAD mutant was still capable of interacting with AMPKβ2,
the WANNA mutation abolished AMPKβ2 binding (Figures 2B,
right panel, and 2C). In good agreement, Y2H analyses using
AMPKβ1 or AMPKβ2 as bait confirmed that the binding of R6
to the AMPKβ subunits depended on the R6 substrate-binding
motif being intact (Figures 2C and 2D). Thus, we show that the
AMPKβ–R6 interaction requires the R6 substrate-binding motif.
In all subsequent experiments, we concentrated on the AMPKβ2–
R6 interaction.
AMPKβ2 Thr-148 mutant shows reduced interaction with R6
Previously, we showed that substitution of arginine for the Gly-
147 residue (G147R) within the β1-CBM domain abolished the
interaction of AMPK with R6 [20], indicating that AMPKβ1
requires the CBM for interaction with R6. More recently, we
demonstrated that autophosphorylation at the β Thr-148 residue,
centrally located in the CBM, prevents AMPK from binding
to carbohydrates such as glycogen [22]. As we show here that
R6 also interacts with AMPKβ2, we next investigated whether
Thr-148 is required for the AMPKβ2–R6 interaction. To this
end, a phospho-mimicking AMPKβ2 mutant was generated by
replacing the Thr-148 residue with aspartate (T148D) within the
β2-CBM. Transiently transfected HEK293T cells co-expressing
FLAG–R6 and AMPK heterotrimers (myc–α1 and γ 1 in
combination with either β2-WT– or β2-T148D–mCherry) were
cultured under high-glucose conditions (25 mM) and used for
co-IP analysis. Impaired interaction between AMPKβ2 and
R6 was observed in cells overexpressing mutant AMPKβ2-
T148D (Figure 3A, right panel); relevantly, FLAG–R6 and β2–
mCherry were expressed at comparable levels (Figure 3A, left
panel). Independent Y2H analyses corroborated these findings:
the T148D mutation decreased the interaction between AMPKβ2
and R6 (Figure 3B). Taken together, our data indicate that Thr-
148 mutation into aspartate results in loss of the AMPKβ2–R6
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Figure 2 R6 interaction with AMPKβ2 requires its substrate-binding motif
(A) Schematic model indicating the PP1- and substrate-binding sites of R6, and its corresponding mutations. (B) HEK293T cells transiently co-expressing AMPKβ2 heterotrimers (myc–α1, γ 1,
AMPKβ2–mCherry) and FLAG–R6-WT (R6-WT) or mutant (R6-RARA, R6-RAHA, R6-WANNA, R6-WDNAD respectively) were continuously cultured under high-glucose (25 mM) conditions and
harvested 48 h post-transfection. FLAG EV was used as control. Interaction between AMPKβ2 and R6 was assessed by immunoprecipitating the heterotrimeric AMPK complex from 450 μg of
lysate using the anti-myc-tag antibody. Western blots were assessed using the indicated antibodies. Representative Western blots are shown. (C and D) Yeast THY-AP4 strain (see the Materials and
methods section) was transformed with GAD-AMPKβ2 (C) or GAD-AMPKβ1 (D) plasmids and LexA-R6 plasmids as indicated. Transformants were grown in high-glucose (4 % glucose) medium and
protein interactions were estimated by measuring the β-galactosidase activity. Values correspond to means from at least six different transformants (bars indicate S.D.). *P < 0.05 and **P < 0.001
compared with LexA-R6-WT.
interaction, suggesting that an intact Thr-148 residue is essential
for the formation of the AMPKβ2–R6 complex under glucose-
rich culturing conditions.
Glycogen depletion enhances the interaction between AMPKβ2
and R6
To investigate whether the interaction between AMPKβ2 and R6
is responsive to variation in glycogen level, we aimed to deplete
cellular glycogen content. Hence, HEK293T cells were either
pharmacologically treated with forskolin, a compound inducing
glycogen breakdown [31], or glucose-deprived, after which
glycogen content was assessed. Because R6 is known to have
glycogenic properties [24], we included non-transfected control
cells and compared these with cells that were either transfected
with FLAG–R6 alone or co-transfected with all three subunits
of AMPK (myc–α1, β2-WT–mCherry, γ 1). As expected, cells
overexpressing FLAG–R6 showed high glycogen content (both in
the absence and presence of overexpressed AMPKβ2 complex):
basal glycogen levels were 30–40-fold increased compared
with non-transfected control cells (Figure 4A). Both forskolin
treatment and glucose deprivation significantly lowered the
intracellular glycogen levels in all cell lines, as compared with
their respective controls (Figure 4A). To assess the effect of
cellular glycogen content on AMPKβ2–R6 interaction, HEK293T
cells overexpressing both FLAG–R6 and AMPKβ2 heterotrimers
were either treated with forskolin or glucose-deprived for 16 h.
Reduction of cellular glycogen content, either by forskolin
treatment or by glucose deprivation, substantially enhanced the
interaction between AMPK and R6 that was accompanied by a
similar increase in the Thr-172 phosphorylation level (Figure 4B,
right panel); as total levels of AMPK and R6 did not change
within the experimental time frame (Figure 4B, left panel),
this ruled out any possible interference by altered expression.
Furthermore, we examined whether the binding of overexpressed
AMPKβ2 to FLAG–R6 is reversible (Figure 4C). Expectedly,
immunoprecipitates of AMPK from cells that were cultured in
low-glucose (3 mM) medium displayed clear interaction with
R6. When cells were switched back to incubation in high-
glucose (25 mM) medium, this association decreased time-
dependently, resulting in a complete loss of the AMPKβ2–
R6 interaction after 30 min. Collectively, our data suggest that
the interaction between AMPKβ2 heterotrimers and R6 is
dynamic and inversely correlated with cellular glycogen level.
To independently examine a possible direct effect of glycogen
on the AMPKβ2–R6 binding, we next used β-CD, a model sugar
that mimics glycogen, in competitive binding IP experiments in
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Figure 3 AMPKβ2 Thr-148 mutant shows reduced interaction with R6
(A) HEK293T cells transiently transfected with myc–α1, γ 1 and mCherry-tagged AMPKβ2 WT or Thr-148 mutant (T148D) were co-transfected either with FLAG–R6 ( + ), or FLAG EV ( − )
as control. Cells were cultured under high-glucose (25 mM) conditions, and harvested 56 h post-transfection. Interaction between AMPKβ2 and R6 was assessed by immunoprecipitating the
heterotrimeric AMPK complex from 800 μg of lysate using the anti-myc-tag antibody. Western blots were assessed using the indicated antibodies. Representative Western blots are shown. (B)
Yeast THY-AP4 strain was transformed with plasmids LexA-AMPKβ2-WT or LexA-AMPKβ2-T148D and GAD-R6 as indicated. Transformants were grown in high-glucose (4 % glucose) medium and
protein interactions were estimated by measuring the β-galactosidase activity. EV pGADT7 (GAD-) served as control. Values correspond to means from at least six different transformants (bars
indicate S.D.). *P < 0.001 compared with LexA-AMPKβ2-WT + GAD-R6.
Figure 4 Glycogen depletion enhances the interaction between AMPKβ2 and R6
(A and B) HEK293T cells non-transfected, transiently transfected with FLAG–R6 alone or co-transfected with FLAG–R6, myc–α1, γ 1 and mCherry-tagged AMPKβ2-WT were cultured under
high-glucose (25 mM) conditions. Prior to lysis, cells were treated with forskolin (100 μM) or DMSO (control) under high-glucose conditions or cells were glucose-deprived (GD, 0 mM) for
16 h. (A) Intracellular glycogen level was determined as described in the Materials and methods section. Levels were corrected for corresponding protein concentrations. *P < 0.05 compared
with corresponding DMSO controls; n = 2. (B) Heterotrimeric AMPK was immunoprecipitated from 500 μg of lysate using the anti-myc-tag antibody, followed by Western blot analysis using
the indicated antibodies. (C) HEK293T cells transiently transfected with FLAG–R6, myc–α1, γ 1 and mCherry-tagged AMPKβ2-WT were cultured under low-glucose (3 mM) conditions and
recovered with high-glucose medium (25 mM) for the indicated time period before lysis and immunoprecipitation. (D) HEK293T cells were transiently co-transfected as indicated and harvested 56 h
post-transfection. Cells were continuously grown under high-glucose (25 mM) conditions. β-CD (5 mM) was added prior to IP. Representative Western blots are shown.
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Figure 5 AMPKβ2–R6 interaction is enhanced in conjunction with increased AMPKβ2 Thr-148 phosphorylation
HEK293T cells were transiently transfected for co-expression of AMPKβ2 heterotrimers (myc–α1, γ 1, mCherry-tagged AMPKβ2-WT or -T148D) and FLAG–R6. (A and B) Prior to lysis, cells were
cultured under various glucose conditions (i.e. 25, 3 or 0 mM) for 16 h. (A) Intracellular glycogen levels were biochemically determined and corrected for the corresponding protein concentrations.
*P < 0.01 compared with WT 25 mM, #P < 0.01 compared with T148D with 25 mM glucose, ##P < 0.001 compared with T148D with 25 mM glucose; n = 2. (B) Heterotrimeric AMPK was
immunoprecipitated from 350 μg of lysate using the anti-myc-tag antibody, followed by Western blot analysis using the indicated antibodies. (C) Cells were either maintained in GM (25 mM
glucose + 10 % iFBS), or serum-starved (5.5 mM glucose) for 16 h and subsequently treated with DMSO (control) or a variety of AMPK activators for 1 h, as indicated. AMPK complexes were
immunoprecipitated from 350 μg of lysate using the anti-myc-tag antibody, followed by Western blot analysis using various antibodies. (D) Cells were serum-starved both under low-(3 mM) and
high-(25 mM) glucose conditions for 16 h, prior to 1 h treatment with oligomycin (3 μM) or DMSO (control). AMPK was immunoprecipitated from 500 μg of lysate as described in (B), followed by
Western blot analysis using the indicated antibodies. Representative Western blots are shown.
HEK293T cells cultured under high glucose. Addition of β-CD
completely disrupted the interaction between AMPKβ2 and R6
(Figure 4D, right panel). Combined, these data suggest that, under
glucose-rich conditions, glycogen disturbs the AMPKβ2–R6
interaction, indicating that glycogen interferes with and therefore
weakens the interaction between AMPKβ2 and R6.
AMPKβ2–R6 interaction is enhanced by glycogen depletion in
conjunction with increased AMPKβ2 Thr-148 phosphorylation
Next, we assessed the impact of Thr-148 phosphorylation on the
glycogen-modulated AMPKβ2–R6 interaction. To this end, we
co-transfected HEK293T cells with AMPK heterotrimers (myc–
α1, γ 1 and either mCherry-tagged β2-WT or -T148D mutant)
and FLAG–R6, and challenged the cells for 16 h with various
concentrations of glucose. The expression of AMPKβ2-T148D
mutant did not affect the glycogenic activity of FLAG–R6 in cells
cultured under high-glucose conditions (Figure 5A), indicating
that glycogen production depends on the function of R6 but not
on the interaction between R6 and AMPKβ2. Reduced availability
of glucose (i.e. 3 or 0 mM) correlated with significantly decreased
intracellular levels of glycogen in both AMPKβ2-WT- and
-T148D-expressing cells (Figure 5A). Interestingly, we observed
increased levels of Thr-148 phosphorylation in β2-WT immun-
oprecipitates upon lowering glucose conditions, although we did
not find changes in the levels of AMPK Thr-172 phosphorylation,
either in cellular lysates or in the precipitates from β2-WT- or
β2-T148D-expressing cells (Figure 5B). Low glycogen content
enhanced AMPKβ2–R6 interaction (Figure 5B; cf. Figure 4).
Whereas AMPKβ2-WT–R6 binding was readily detectable,
T148D mutation completely abolished AMPKβ2 interaction
with R6, independent of the glycogen status (Figure 5B; cf.
Figure 3). Furthermore, we investigated the effect of AMPK
activation on the AMPKβ2–R6 interaction using various AMPK-
activating stimuli (Figure 5C). Again, the AMPKβ2-T148D
mutant did not associate with R6 under any of the conditions
tested. AMPK activation generally enhanced the AMPKβ2-
WT–R6 interaction. Oligomycin exhibited the strongest AMPK-
activating effect (Thr-172 phosphorylation in Figure 5C, left
panel). AMPKβ2 Thr-148 phosphorylation and the binding of R6
to AMPKβ2 were greatly enhanced by oligomycin (Figure 5C,
right panel). Next, we exposed cells to oligomycin in the context
of high and low cellular glycogen. If glycogen content was
low (i.e. 3 mM glucose), oligomycin activated AMPK (Thr-172
phosphorylation; Figure 5D), an effect that was overruled by
high cellular glycogen content (i.e. 25 mM glucose). Oligomycin
induced activation of AMPK and the consequential Thr-148
phosphorylation further enhanced the interaction of AMPKβ2-
WT and R6 (Figure 5D, right panel) under low glycogen
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Figure 6 Endogenous AMPKβ2 shows enhanced interaction with R6 upon glycogen depletion in C2C12 myotubes
C2C12 cells stably overexpressing FLAG–R6 were differentiated into myotubes for 4–5 days, and subsequently incubated with high (25 mM) or low (3 mM) glucose for 16 h, followed by 30 min of
treatment with oligomycin (5 μM) or DMSO (control). pBabe-puromycin EV was used as control. (A) Myocellular glycogen levels were determined using a biochemical glycogen assay, as described
in the Materials and methods section. *P < 0.05 and **P < 0.001; n = 3. (B) Interaction between AMPKβ2 and R6 was assessed by IP using the anti-FLAG-tag antibody, followed by Western
blot analysis using the indicated antibodies. (C) Interaction between AMPKβ2 and R6 was assessed by IP using anti-AMPKα1/α2 antibodies, followed by Western blot analysis using the indicated
antibodies. (D) Mouse gastrocnemius muscle lysate was cleared by centrifugation and subjected to IP using AMPK α1/AMPKα2 antibodies. Immunoprecipitates were maintained on ice either
untreated or treated with CIP and then probed by Western blotting using the indicated antibodies. Representative Western blots are shown.
conditions. This interaction was disrupted by high cellular
glycogen or by T148D mutation (Figure 5D). These results
indicate that glycogen depletion enhances both the AMPKβ2-
R6 interaction and phosphorylation of Thr-148. Our data also
indicate that phosphorylation of AMPKβ2 at Thr-148 has a
different outcome from the AMPKβ2-T148D mutant: whereas
the AMPKβ2-T148D mutant is not able to interact with R6,
the AMPKβ2-R6 interaction is improved under conditions that
enhance AMPKβ2 Thr-148 phosphorylation.
Endogenous AMPKβ2 shows enhanced interaction with R6 upon
glycogen depletion in C2C12 myotubes
Furthermore, we explored the significance of cellular glycogen
with respect to the AMPKβ2-R6 interaction in C2C12 myotubes,
a more physiologically relevant model. Similar to all other
tested cell types, endogenous R6 was below detection level in
C2C12 cells using a variety of available antibodies (results not
shown). Hence, we stably expressed FLAG–R6 or EV control
in C2C12 myoblasts. C2C12 cells were then differentiated to
myotubes and cultured under high- (i.e. 25 mM) or low- (i.e.
3 mM) glucose concentrations prior to oligomycin treatment.
We determined glycogen content and AMPKβ2-R6 interaction
for each condition (Figures 6A and 6B). Both lowered
glucose availability and oligomycin treatment reduced the
myocellular glycogen content below detection level in cells
expressing the EV control (Figure 6A). R6 overexpression
greatly enhanced the levels of glycogen under basal and treated
conditions (Figure 6A). Oligomycin challenged the glycogen
levels (Figure 6A) and clearly induced AMPK activation in
C2C12 myotubes, under both high- and low-glucose conditions
(Figure 6B, left panel). However, as in HEK293T cells,
oligomycin-mediated AMPK activation could only be detected
in immunoprecipitates from cells that were cultured under low-
glycogen conditions (Figure 6B, right panel). As expected,
increased interaction of AMPKβ2 with R6 was detected after
immunoprecipitating FLAG–R6 from oligomycin-treated cells
under low-glycogen conditions (Figure 6B, right panel). By
performing the reverse IP using AMPKα1/AMPKα2-directed
antibodies, we also detected enhanced FLAG–R6 presence under
low-glycogen conditions (Figure 6C). Moreover, we detected Thr-
148 phosphorylation of endogenous AMPKβ2, which expectedly
was highest in conjunction with low glycogen in oligomycin-
treated immunoprecipitates (Figure 6C). We further assessed the
presence of Thr-148 phosphorylation in a physiological context.
Gastrocnemius muscle was obtained from untreated mice and
AMPK was immunoprecipitated from homogenates (Figure 6D).
As shown by Western blotting, Thr-148 phosphorylation signal
was evident. A decrease in this signal upon incubation with calf
intestine phosphatase (CIP) further confirms the phosphorylation
event. Therefore, skeletal muscle may operate signalling pathways
involving phosphorylated Thr-148. Taken together, in good
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Figure 7 AMPKβ2 Thr-148 mutant enhances glycogen content of C2C12 myotubes
C2C12 cells stably overexpressing AMPKβ2-WT or -T148D mutant were differentiated into myotubes for 4–5 days, and subsequently incubated with high (25 mM), low (3 mM) or no (0 mM) glucose
for 16 h. (A) Myocellular glycogen levels were determined using a biochemical glycogen assay, as described in the Materials and methods section. *P < 0.01 compared with β2-WT with 25 mM
glucose, #P < 0.05 compared with β2-T148D with 25 mM glucose, $P < 0.05 β2-WT compared with β2-T148D; n = 2. (B) Insulin-stimulated glucose uptake was determined as described in the
Materials and methods section. *P < 0.01 compared with β2-WT with 25 mM glucose, #P < 0.01 compared with β2-T148D with 25 mM glucose, $P < 0.01 β2-WT compared with β2-T148D;
n = 2.
agreement with our observations in HEK293T cells, the data
obtained from C2C12 myotubes support the notion that cellular
glycogen content controls AMPKβ2-R6 binding. Also, Thr-
148 phosphorylation of endogenous AMPKβ2 occurred in
conjunction with R6 interaction in C2C12 myotubes.
AMPKβ2 Thr-148 mutant enhances glycogen content of C2C12
myotubes
We next studied the effect of expressing the AMPKβ2-T148D
mutant in C2C12 cells in terms of glucose uptake and glycogen
accumulation. To this end, we stably expressed AMPKβ2-WT
or -T148D mutant in C2C12 cells, and after differentiation, cells
were incubated in the presence of high (25 mM), low (3 mM)
or no glucose. Expectedly, the glycogen levels were challenged
by low or no glucose incubations (Figure 7A). However,
relative to WT, the T148D mutant-overexpressing cells showed
significantly higher glycogen content (under high glucose). Since
the AMPKβ2-T148D mutant does not associate with glycogen
(and R6), these data could indicate a function of the AMPKβ2-
T148D mutant that is independent of the glycogen particle,
possibly by improving glucose uptake. Indeed, glucose uptake
was significantly higher in AMPKβ2-T148D-expressing cells
if compared with AMPKβ2-WT under all culturing conditions
(Figure 7B).
DISCUSSION
In the present study, we demonstrate the involvement of Thr-
148 in the dynamic AMPKβ2-R6 interaction that is governed by
glycogen content.
Due to the positioning of Thr-148 in the carbohydrate-binding
pocket, the phosphorylation of this residue is incompatible with
glycogen binding. Glucose deprivation expectedly resulted in
reduced glycogen levels (Figures 4–7). Accordingly, we detected
strong AMPKβ2 Thr-148 phosphorylation signals only when
glycogen levels were low, which were further augmented by
oligomycin treatment (Figure 5). Similar to GS, which dissociates
from glycogen in response to glycogen breakdown [32,33],
decreased glycogen content may also cause AMPKβ2 and R6
to leave glycogen. In support of such notion, oligomycin-induced
AMPK activation augmented AMPKβ2-R6 interaction also in
C2C12 myotubes, while further depleting glycogen and inducing
Thr-148 phosphorylation (Figure 6), strongly suggesting that
these events are linked. In conjunction with lowered glycogen
content, oligomycin-induced Thr-172 phosphorylation was also
more effective, which ties in with autophosphorylation of Thr-
148, i.e. by AMPK. Thus, autophosphorylation of Thr-148 by
AMPK may indicate detachment of AMPK from glycogen under
conditions that challenge the cellular glycogen level.
We find that phosphorylation of AMPKβ2 at Thr-148 enhanced
the binding to R6, whereas AMPKβ2-R6 interaction was
completely lost in the AMPKβ2-T148D mutant. The latter results
are in agreement with earlier observations, where the AMPKβ1-
G147R mutation impaired the ability to interact with R6 [20].
Since AMPKβ Thr-148 is located adjacent to Gly-147, a similar
loss of binding to R6 for the Thr-148 mutant was expected.
Nevertheless, the molecular mechanism explaining the loss of
binding to R6 as a result of T148D mutation remains unclear
because Thr-148 phosphorylation was enhanced in conjunction
with the AMPKβ2-R6 interaction (Figure 5). In our previous
study, we found that the T148D mutant did not bind glycogen
[22]. Hence, there are at least two possible explanations: (i) the
T148D mutation causes a subtle modification in the conformation
of the β2 subunit resulting in the loss of interaction with R6,
a process not shared by the physiological phosphorylation of
this subunit, or (ii) the interaction of AMPKβ2-WT with R6
that is observed during glycogen degradation evolves from their
initial binding at glycogen. These explanations are not mutually
exclusive and we formally cannot rule out the former, but there are
arguments in support of the latter notion. First, both AMPKβ2 and
R6 bind to glycogen via their respective CBM [12,34]. The co-
localization of AMPK and R6 to glycogen brings them in close
proximity to each other, which may facilitate their subsequent
direct interaction, i.e. as a second step during conditions that
degrade glycogen. Hence, the possible mechanisms causing
AMPKβ2 and R6 to leave the dwindling glycogen particle may
include the decreasing surface-binding options. On a diminishing
glycogen granule, we can indeed expect the concentration of
potential interaction partners to increase dramatically, which may
facilitate a direct binding between these proteins concomitant
with their detachment from glycogen. This is in accordance with
our findings showing that depletion of intracellular glycogen
resulted in enhanced AMPKβ2-R6 interaction (Figures 4–6).
In particular, the AMPKβ2-R6 complex was more abundant in
glucose-deprived or forskolin-treated cells (Figure 4B). Similarly,
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in earlier Y2H analyses, low-glucose medium augmented the
AMPKβ1-R6 interaction [35]. Secondly, high glycogen content
was found to decrease the AMPKβ2-R6 interaction (Figures 4–
6), and thus glycogen may in fact rather perturb the direct binding
between AMPKβ2 and R6. In addition, AMPKβ2-R6 binding
decreased upon treatment of co-IPs with β-CD (Figure 4D). Since
the R6-substrate-binding motif partially overlaps with the CBM
domain [23], it is conceivable that glycogen competes with R6
binding to AMPK. Thus, our data suggest that low glycogen
favours AMPKβ2-R6 interaction, whereas high glycogen content
interferes with it. We propose that the AMPKβ2-T148D mutant,
due to lack of glycogen-binding affinity, is excluded from the
interaction with R6 because this process initiates at glycogen.
AMPK plays an essential role in various biological processes
involved in restoring cellular energy homoeostasis. Tuning of
such processes requires adequate regulation, and involves AMPK
compartmentalization and complex formation with other proteins
and substrates. In the present study, we show that R6 preferentially
interacts with AMPKβ2, rather than AMPKβ1, pointing to
a possible role for this interaction in skeletal muscle. The
CBM domain of AMPKβ2 possesses higher binding affinity
for carbohydrates such as glycogen than AMPKβ1 [14]. In a
more detailed study, the CBM domain of AMPKβ2 bound linear
carbohydrates and single α1,6-branched carbohydrates 4–30-fold
tighter in comparison with AMPKβ1 [36]. AMPKβ2, as well as
R6, are highly expressed in skeletal muscle [3,37], a tissue active
in controlling disposal of glucose into glycogen [38]. Thus, it is
likely that these proteins contribute to the regulation of myocel-
lular glycogen turnover. In vivo studies seemingly contradict the
importance of AMPKβ2 in glycogen metabolism: The observed
differences in glycogen content were marginal between WT and
AMPKβ1/β2-double-knockout mice pre- and post-exercise [39].
In AMPKβ2-knockout mice, muscular glycogen content was
reduced pre-exercise and was equal with a slight tendency to
increase post-exercise [6,7]. However, since there is a reduction
in the levels of skeletal muscle AMPKα1 and AMPKα2 in
AMPKβ2-knockout mice and a dramatic reduction of the levels
of the AMPK complex subunits in double AMPKβ1/AMPKβ2-
knockout mice, it is difficult to make any correlation between the
levels of glycogen in these mice and the activity of AMPK. We
recently showed that activation of AMPK precedes AMPKβ Thr-
148 autophosphorylation to preclude the AMPK complex from
binding to glycogen and further data suggested a possible role
for Thr-148 phosphorylation in glycogen turnover in several cell
lines [22]. Thus, independently of possible functions for AMPK
complexes that are bound at glycogen particles, free cytosolic
AMPK may also indirectly affect glycogen metabolism, as
further supported by T148D overexpression in C2C12 myotubes
(Figure 7). Moreover, R6 is a known glycogen-binding protein
and PP1-targeting subunit acting as a glycogenic driver [24].
Hence, it is conceivable to expect that the AMPKβ2-R6
interaction is playing an important role in glycogen metabolism in
muscle.
In yeast, it was reported earlier that Gal-83 (Snf1 β-subunit
orthologue) is involved in binding to Reg1 (PP1 glycogenic
subunit orthologue) and studies in mouse pancreatic β-cells
revealed that AMPKβ1 interacts with the PP1 glycogen-targeting
subunit R6 [20,40]. R6 recruits PP1 to its substrates (e.g. GS and
GP) [23], thus playing a critical role in the regulation of glycogen
metabolism. Most of the PP1 glycogen-targeting subunits exert
their actions through binding to PP1 via a conserved N-terminal
PP1-binding motif (RVXF), and interact with PP1 substrates via
a conserved C-terminal substrate-binding [WXNXGNYX(L/I)]
motif [23]. We have recently shown that R6 utilizes this conserved
region to bind to its glycogenic substrates GS and GP [23]. In line
with these results, our work indicates that AMPKβ/R6 interaction
occurs also via the R6 substrate-binding motif (Figure 2), as a
mutation in this domain resulted in loss of interaction, a process
that is independent of PP1 binding. However, we did not find
evidence for R6/PP1-dependent AMPK dephosphorylation in
our study under conditions where the AMPKβ2-R6 interaction
was enhanced. This may be attributed to the use of glycogen
depletion and mitochondrial poisoning as triggers. Although
we find that these treatments are required to induce significant
AMPKβ2-R6 interaction, their application necessarily goes along
with elevated AMP levels and consequent protection from Thr-
172 dephosphorylation [41]. In MIN6 pancreatic β-cells, the
PP1-R6 complex was responsible for AMPK dephosphorylation
at Thr-172 in response to high extracellular glucose [20]. In
HEK293T cells, we find that glucose re-availability leads to
a transient decrease in Thr-172 phosphorylation (Figure 4C).
In the same experiment, AMPKβ2-R6 interaction disappeared
time-dependently after recovery with high glucose. Hence, the
idea that R6 could act as a scaffold to bring AMPKβ2 in close
proximity to the PP1 phosphatase warrants further investigation.
The present data establish that AMPKβ2-R6 complex formation
and dissociation are reversible and dynamic processes that involve
the substrate-binding site of R6. Taken together, we shed new light
on the molecular events that govern the interaction of AMPK
with R6.
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